8-K: 10x Genomics Narrows Losses, Boosts Cash in 2025

10x Genomics reported significantly reduced net and operating losses for Q4 and full year 2025, alongside a strong cash position and new strategic partnerships, while forecasting modest revenue growth for 2026.

Summary

• Revenue for the fourth quarter of 2025 increased by 1% to $166.0 million compared to $165.0 million in the prior year period.
• Full year 2025 revenue was $642.8 million, a 5% increase from $610.8 million in 2024; however, excluding $44.1 million in non-recurring patent litigation settlements, full-year revenue decreased by 2% to $598.7 million.
• Net loss for Q4 2025 significantly improved to $16.3 million from $49.0 million in Q4 2024.
• Full year 2025 net loss dramatically decreased to $43.5 million from $182.6 million in 2024.
• Operating loss for Q4 2025 was $19.5 million, a substantial improvement from $49.8 million in Q4 2024.
• Full year 2025 operating loss was $61.0 million, a significant reduction from $194.6 million in 2024.
• Gross margin improved to 68% for Q4 2025 (from 67%) and 69% for full year 2025 (from 68%).
• Operating expenses decreased by 18% in Q4 2025 and 17% for full year 2025, partly due to lower outside legal expenses, personnel expenses, and a $49.9 million gain on litigation settlements in 2025.
• Cash and cash equivalents and marketable securities ended 2025 at $523.4 million, an increase of $130.0 million over the prior year.
• The company announced new partnerships with the Cancer Research Institute and PharosAI to build AI-ready datasets for cancer research.
• A collaboration with Dana-Farber Cancer Institute was initiated for multi-year research into single cell and spatial tumor analysis for diagnostics.
• A study with Brigham & Women's Hospital was launched to identify single cell blood-based signatures for autoimmune disease.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive report. While underlying revenue growth is modest and even declined when excluding one-time items, the significant improvements in net and operating losses, coupled with a strong cash position and strategic partnerships, indicate improved operational efficiency and a solid foundation for future growth.

Positives

• Net loss significantly improved to $16.3 million in Q4 2025 from $49.0 million in Q4 2024, and to $43.5 million for full year 2025 from $182.6 million in 2024.
• Operating loss substantially decreased to $19.5 million in Q4 2025 from $49.8 million in Q4 2024, and to $61.0 million for full year 2025 from $194.6 million in 2024.
• Gross margin improved to 68% in Q4 2025 and 69% for full year 2025, driven by lower inventory write-downs, royalty costs, and warranty costs.
• Operating expenses decreased significantly due to lower outside legal and personnel expenses, and a $49.9 million gain on litigation settlements.
• Cash and cash equivalents and marketable securities increased by $130.0 million to $523.4 million by December 31, 2025, indicating strong liquidity.
• New strategic partnerships with Cancer Research Institute, PharosAI, Dana-Farber Cancer Institute, and Brigham & Women's Hospital expand platform utility and market reach, particularly in AI-driven demand and clinical applications.

Negatives

• Full year 2025 revenue, excluding non-recurring patent litigation settlements, decreased by 2% to $598.7 million from $610.8 million in 2024, indicating a decline in core product and services revenue.
• Instruments revenue declined in both Q4 2025 (from $24.35 million to $15.47 million) and full year 2025 (from $92.72 million to $56.78 million).
• The 2026 revenue guidance of $600 million to $625 million represents only 0% to 4% growth over full year 2025 (excluding non-recurring revenue), suggesting modest near-term growth expectations.

Future Outlook

10x Genomics expects full year 2026 revenue to be in the range of $600 million to $625 million. Excluding the non-recurring license and royalty revenue related to patent litigation settlements in 2025, this represents 0% to 4% growth over full year 2025. Management is excited by the expanding impact of their platforms, driven by new product innovations and strategic partnerships, and is well positioned to execute across multiple growth vectors, especially AI-driven demand, translational research, and emerging clinical opportunities.

Management Comments

• "In 2025, our team executed with discipline through a challenging environment while continuing to strengthen the fundamentals of the business."
• "As we look to 2026, I am excited by the expanding impact of our platforms, driven by new product innovations and strategic partnerships."
• "We are well positioned to execute across multiple growth vectors in the business, especially AI-driven demand, translational research and emerging clinical opportunities."

Industry Context

StockSavvy.ai notes that 10x Genomics' focus on single cell and spatial biology platforms, coupled with strategic partnerships in AI-driven cancer research and autoimmune disease, positions the company within high-growth segments of the life sciences industry. The emphasis on transforming clinical samples into high-resolution insights aligns with broader trends towards precision medicine and the increasing integration of AI in drug discovery and diagnostics. While core revenue growth (excluding one-time items) has been modest, the strategic moves into clinical applications and AI datasets are critical for long-term relevance and competitive positioning against other genomics and biotech firms.

Stakeholder Impact

• Shareholders: Benefit from significantly reduced losses, improved gross margins, and a stronger cash position, which de-risks the company's financial health. Strategic partnerships could drive long-term value, though core revenue growth remains a watch point.
• Customers (academic and biopharmaceutical researchers): Will benefit from expanded platform capabilities and new research initiatives through partnerships, potentially leading to more comprehensive biological insights and accelerated discoveries.
• Employees: Personnel expenses decreased, which could imply workforce optimization, but the company's strategic focus on growth vectors suggests continued innovation and potential for future opportunities.

Next Steps

• Host a conference call on February 12, 2026, to discuss financial results, business developments, and outlook.
• Continue to execute across multiple growth vectors, including AI-driven demand, translational research, and emerging clinical opportunities.
• Pursue new product innovations and strategic partnerships to expand the impact of platforms.

Key Dates

Recommendation

The recommendation is 'hold' for 10x Genomics. While the company demonstrated significant improvements in profitability, substantially reducing net and operating losses, and strengthened its cash position, the underlying revenue growth (excluding one-time litigation settlements) was negative for the full year 2025 and the 2026 guidance indicates only modest growth. The strategic partnerships and focus on AI-driven demand are positive long-term drivers, but the immediate revenue trajectory suggests a cautious stance. Investors should monitor the execution of these strategic initiatives and the acceleration of core revenue growth before considering a stronger position.

Keywords

10x Genomics, TXG, Financial Results, Earnings, Single Cell Biology, Spatial Biology, Biotechnology, Life Science Technology, Cancer Research, Autoimmune Disease, AI-driven demand, Translational Research, Clinical Opportunities